CoChat

Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders

Open access
Sanacora, Gerard, Zarate, Carlos A., Krystal, John H., Manji, Husseini K. · 2008 · Nature Reviews Drug Discovery

The DOI matches its Crossref record; 187 of the 187 references it cites were found in a registry or an index.

Abstract

Mood disorders are common, chronic, recurrent mental illnesses that affect the lives of millions of individuals worldwide. To date, the monoaminergic systems (serotonergic, noradrenergic and dopaminergic) in the brain have received the greatest attention in neurobiological studies of mood disorders, and most therapeutics target these systems. However, there is growing evidence that the glutamatergic system is central to the neurobiology and treatment of these disorders. Here, we review data supporting the involvement of the glutamatergic system in mood-disorder pathophysiology as well as the efficacy of glutamatergic agents in mood disorders. We also discuss exciting new prospects for the development of improved therapeutics for these devastating disorders.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/nrd2462

Cites

187 of 187 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 187 references

Research works printed but not linked: 1

  1. Preskorn, S. et al. A placebo-controlled trial of the NR2B subunit specific NMDA antagonist CP-101,606 plus paroxetine for treatment resistant depression (TRD). Annual Conference of the American Psychological Association (San Francisco, California) 154 (2007).

Cited by

See all 1,000

Metadata

Authors
Sanacora, G., Zarate, C. A., Krystal, J. H., & Manji, H. K.
Affiliations
  • Yale University (US)
  • National Institutes of Health (US)
Corresponding author
Manji, Husseini K.
Venue
Nature Reviews Drug Discovery
Published
2008-05
Volume
7
Issue
5
Pages
426-437
ISSN
  • 1474-1776 (ISSN-L)
  • 1474-1784
OpenAlex
W2074907255
Cited by
894
References
186
Citations by year
2026: 17 · 2025: 29 · 2024: 33 · 2023: 44 · 2022: 36 · 2021: 44 · 2020: 56 · 2019: 43 · 2018: 40 · 2017: 50 · 2016: 63 · 2015: 70 · 2014: 59 · 2013: 56 · 2012: 68
FWCI
6.71
Type
journal article
Language
en
Open access
Licence
www.springer.com/tdm (tdm)
Locations
  • Nature Reviews Drug Discovery (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • National Institutes of Health
  • National Institute of Mental Health (K02MH076222, Z01MH002828, Z01MH002857)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
Keywords
glutamatergic system, mood disorders, antidepressants, neuroplasticity, glutamatergic agents, monoaminergic systems, rapid-acting antidepressants, drug development
MeSH terms
Animals, Glutamates, Humans, Psychotropic Drugs, Excitatory Amino Acid Antagonists, Mood Disorders

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. https://app.cochat.ai/papers/10.1038/nrd2462
The paper
Sanacora, G., Zarate, C. A., Krystal, J. H., & Manji, H. K. (2008). Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. Nature Reviews Drug Discovery. https://doi.org/10.1038/nrd2462

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.